BioTuesdays

Tag - Swayampakula Ramakanth

Markets

HCW starts Corcept Therapeutics at buy; PT $18

H.C. Wainwright launched coverage of Corcept Therapeutics (NASDAQ:CORT) with a “buy” rating and $18 price target. The stock closed at $12.59 on Sept. 5. Corcept is focused on development and commercialization of...

September 6, 2019
INmune Bio
Markets

HCW starts INmune Bio at buy; PT $11.50

H.C. Wainwright launched coverage of INmune Bio with a “buy” rating and price target of $11.50. The stock closed at $5.94 on Aug. 20. INmune Bio is an immunology company developing therapies targeting innate immunity to...

August 21, 2019
Tocagen Logo
Markets

HCW starts Tocagen at buy; PT $14.50

H.C. Wainwright initiated coverage of Tocagen (NASDAQ:TOCA) with a “buy” rating and price target of $14.50. The stock closed at $9.64 on June 8. Analyst Swayampakula Ramakanth writes that the company’s lead product...

June 11, 2018